221. 抗糸球体基底膜腎炎 Disease details / Clinical trials / Drug dev / DR info /
臨床試験数 : 9 / 薬物数 : 8 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 20
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
Cyclophosphamide
Hansa Biopharma AB
2022 Phase 3 NCT05679401 Austria;Belgium;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Shanghai Bao Pharmaceuticals Co., Ltd.
2024 Phase 2 NCT06607016 China
Eculizumab
Peking University First Hospital
2024 Phase 2 NCT06513338 China
Efalizumab
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal
Glucocorticoids
Hansa Biopharma AB
2022 Phase 3 NCT05679401 Austria;Belgium;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Shanghai Bao Pharmaceuticals Co., Ltd.
2024 Phase 2 NCT06607016 China
HMED-ides
Mårten Segelmark
2017 Phase 2 NCT03157037 Austria;Czechia;Denmark;France;Sweden
Imlifidase
Hansa Biopharma AB
2022 Phase 3 NCT05679401 Austria;Belgium;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
KJ103 FOR injection
Shanghai Bao Pharmaceuticals Co., Ltd.
2024 Phase 2 NCT06607016 China
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal
Hansa Biopharma AB
2022 Phase 3 NCT05679401 Austria;Belgium;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Shanghai Bao Pharmaceuticals Co., Ltd.
2024 Phase 2 NCT06607016 China
Eculizumab
Peking University First Hospital
2024 Phase 2 NCT06513338 China
Efalizumab
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal
Glucocorticoids
Hansa Biopharma AB
2022 Phase 3 NCT05679401 Austria;Belgium;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Shanghai Bao Pharmaceuticals Co., Ltd.
2024 Phase 2 NCT06607016 China
HMED-ides
Mårten Segelmark
2017 Phase 2 NCT03157037 Austria;Czechia;Denmark;France;Sweden
Imlifidase
Hansa Biopharma AB
2022 Phase 3 NCT05679401 Austria;Belgium;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
KJ103 FOR injection
Shanghai Bao Pharmaceuticals Co., Ltd.
2024 Phase 2 NCT06607016 China
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal